Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Laminaria digitata and Palmaria palmata Seaweeds as Natural Source of Catalysts for the Cycloaddition of CO₂ to Epoxides.

Comerford JW, Gray T, Lie Y, Macquarrie DJ, North M, Pellis A.

Molecules. 2019 Jan 12;24(2). pii: E269. doi: 10.3390/molecules24020269.

2.

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients.

Xu SS, Alexander PK, Lie Y, Dore V, Bozinovski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

BMJ Open. 2018 Nov 15;8(11):e025533. doi: 10.1136/bmjopen-2018-025533.

3.

p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.

Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie YS, Petropoulos CJ, Weidler J, Joensuu H.

Clin Cancer Res. 2018 Jul 1;24(13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. Epub 2018 Mar 13.

4.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

5.

Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET.

Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

J Nucl Med. 2017 Nov;58(11):1815-1820. doi: 10.2967/jnumed.116.189019. Epub 2017 May 10.

6.

Effective management of patients with acute ischemic stroke based on lean production on thrombolytic flow optimization.

Liang Z, Ren L, Wang T, Hu H, Li W, Wang Y, Liu D, Lie Y.

Australas Phys Eng Sci Med. 2016 Dec;39(4):987-996. doi: 10.1007/s13246-016-0442-1. Epub 2016 Apr 19.

PMID:
27094731
7.

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL.

HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585.

PMID:
26899540
8.

Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.

Yardley DA, Kaufman PA, Huang W, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, Adams JW, Lie Y, Paquet AC, Sperinde J, Haddad M, Anderson S, Brigino M, Pesano R, Bates MP, Weidler J, Bosserman L.

Breast Cancer Res. 2015 Mar 18;17:41. doi: 10.1186/s13058-015-0543-x.

9.

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.

Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J.

Neuro Oncol. 2015 Sep;17(9):1241-9. doi: 10.1093/neuonc/nov012. Epub 2015 Feb 13.

10.

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA.

J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.

11.

Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients.

Arruda LB, Araújo ML, Martinez ML, Gonsalez CR, Duarte AJ, Coakley E, Lie Y, Casseb J.

Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):287-90.

12.

Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.

Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J.

Clin Cancer Res. 2014 May 15;20(10):2805-13. doi: 10.1158/1078-0432.CCR-13-2782. Epub 2014 Mar 25.

13.

How to improve the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis in pain management in patients with pancreatic cancer: analysis in a single center.

Si-Jie H, Wei-Jia X, Yang D, Lie Y, Feng Y, Yong-Jian J, Ji L, Chen J, Liang Z, De-Liang F.

Surg Laparosc Endosc Percutan Tech. 2014 Feb;24(1):31-5. doi: 10.1097/SLE.0000000000000032.

14.

CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.

Meditz AL, Folkvord JM, Lyle NH, Searls K, Lie YS, Coakley EP, McCarter M, Mawhinney S, Connick E.

J Infect Dis. 2014 Mar;209(6):922-30. doi: 10.1093/infdis/jit575. Epub 2013 Oct 31.

15.

Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Ransy DG, Motorina A, Merindol N, Akouamba BS, Samson J, Lie Y, Napolitano LA, Lapointe N, Boucher M, Soudeyns H.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):312-24. doi: 10.1089/AID.2013.0155. Epub 2013 Oct 25. Erratum in: AIDS Res Hum Retroviruses. 2014 May;30(5):509.

16.

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.

Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.

Breast Cancer Res Treat. 2013 Aug;141(1):43-53.

17.

HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization.

Pou C, Codoñer FM, Thielen A, Bellido R, Pérez-Álvarez S, Cabrera C, Dalmau J, Curriu M, Lie Y, Noguera-Julian M, Puig J, Martínez-Picado J, Blanco J, Coakley E, Däumer M, Clotet B, Paredes R.

PLoS One. 2013 Aug 1;8(8):e67085. doi: 10.1371/journal.pone.0067085. Print 2013.

18.

HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, Verhofstede C, Lie Y, Seguin-Devaux C, Schmit JC, Bercoff DP.

PLoS One. 2013 May 8;8(5):e60566. doi: 10.1371/journal.pone.0060566. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/7c0b830d-e75d-4128-ab54-7d5ecfd99d19.

19.

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.

Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA.

Retrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.

20.

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.

Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY.

PLoS One. 2012;7(7):e39943. doi: 10.1371/journal.pone.0039943. Epub 2012 Jul 27.

21.

Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients.

Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M.

HIV Med. 2012 Jul;13(6):345-51. doi: 10.1111/j.1468-1293.2011.00981.x. Epub 2012 Jan 26.

22.

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz B, Wysocki P, Jankowski T, Radecka B, Foszczynska-Kłoda M, Litwiniuk M, Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J.

Oncologist. 2012;17(1):26-35. doi: 10.1634/theoncologist.2011-0212. Epub 2012 Jan 10. Erratum in: Oncologist. 2013;18(6):775.

23.

Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Lie Y, Coakley E, Hammer SM, Brudney K.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):667-74. doi: 10.1089/AID.2010.0355. Epub 2011 Sep 23. Review.

24.

Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.

Green TN, Archary M, Gordon ML, Padayachi N, Lie Y, Anton ED, Reeves JD, Grobler A, Bobat R, Coovadia H, Ndung'u T.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):324-32. doi: 10.1089/aid.2011.0106. Epub 2011 Aug 5.

25.

HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.

Meditz AL, Haas MK, Folkvord JM, Melander K, Young R, McCarter M, Mawhinney S, Campbell TB, Lie Y, Coakley E, Levy DN, Connick E.

J Virol. 2011 Oct;85(19):10189-200. doi: 10.1128/JVI.02529-10. Epub 2011 Aug 3.

26.

Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options.

Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, Lie Y, Anton ED, Murphy R, Reeves JD, Kuritzkes DR, Ndung'u T.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):233-40. doi: 10.1097/QAI.0b013e318228667f.

27.

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.

Paquet AC, Baxter J, Weidler J, Lie Y, Lawrence J, Kim R, Bates M, Coakley E, Chappey C.

PLoS One. 2011 Jan 31;6(1):e14638. doi: 10.1371/journal.pone.0014638.

28.

Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.

Bates M, Sperinde J, Köstler WJ, Ali SM, Leitzel K, Fuchs EM, Paquet A, Lie Y, Sherwood T, Horvat R, Singer CF, Winslow J, Weidler JM, Huang W, Lipton A.

Ann Oncol. 2011 Sep;22(9):2014-20. doi: 10.1093/annonc/mdq706. Epub 2011 Feb 2.

PMID:
21289364
29.

Very high quantitative tumor HER2 content and outcome in early breast cancer.

Joensuu H, Sperinde J, Leinonen M, Huang W, Weidler J, Bono P, Kataja V, Kokko R, Turpeenniemi-Hujanen T, Jyrkkiö S, Isola J, Kellokumpu-Lehtinen PL, Paquet A, Lie Y, Bates M.

Ann Oncol. 2011 Sep;22(9):2007-13. doi: 10.1093/annonc/mdq710. Epub 2011 Feb 1.

PMID:
21285132
30.

HIV tropism and decreased risk of breast cancer.

Hessol NA, Napolitano LA, Smith D, Lie Y, Levine A, Young M, Cohen M, Minkoff H, Anastos K, D'Souza G, Greenblatt RM, Goedert JJ.

PLoS One. 2010 Dec 16;5(12):e14349. doi: 10.1371/journal.pone.0014349.

31.

Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, Lie YS, Whitby FG, Eckert DM, Hill CP, Root MJ, Kay MS.

J Virol. 2010 Nov;84(21):11235-44. doi: 10.1128/JVI.01339-10. Epub 2010 Aug 18.

32.

HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Wyman N, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long Term Monitoring Study (CPCRA060) Terry Beirn Community Programs for Clinical Research on AIDS.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.

33.

Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.

Coakley E, Reeves JD, Huang W, Mangas-Ruiz M, Maurer I, Harskamp AM, Gupta S, Lie Y, Petropoulos CJ, Schuitemaker H, van 't Wout AB.

Antimicrob Agents Chemother. 2009 Nov;53(11):4686-93. doi: 10.1128/AAC.00229-09. Epub 2009 Aug 17.

34.

Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. Erratum in: J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):238.

35.

Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long-Term Monitoring Study (CPCRA 060) and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259-66. doi: 10.1097/QAI.0b013e3181989a8b. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.

36.
37.

A public health model for the molecular surveillance of HIV transmission in San Diego, California.

Smith DM, May SJ, Tweeten S, Drumright L, Pacold ME, Kosakovsky Pond SL, Pesano RL, Lie YS, Richman DD, Frost SD, Woelk CH, Little SJ.

AIDS. 2009 Jan 14;23(2):225-32. doi: 10.1097/QAD.0b013e32831d2a81.

38.

DNA analysis in perpetrator identification of terrorism-related disaster: suicide bombing of the Australian Embassy in Jakarta 2004.

Sudoyo H, Widodo PT, Suryadi H, Lie YS, Safari D, Widjajanto A, Kadarmo DA, Hidayat S, Marzuki S.

Forensic Sci Int Genet. 2008 Jun;2(3):231-7. doi: 10.1016/j.fsigen.2007.12.007. Epub 2008 Feb 12.

PMID:
19083826
39.

Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration.

Cachay ER, Moini N, Kosakovsky Pond SL, Pesano R, Lie YS, Aiem H, Butler DM, Letendre S, Mathews WC, Smith DM.

Open AIDS J. 2007;1:5-10. doi: 10.2174/1874613600701010005. Epub 2007 Oct 22.

40.

Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.

De Luca A, Weidler J, Di Giambenedetto S, Coakley E, Cingolani A, Bates M, Lie Y, Pesano R, Cauda R, Schapiro J.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):411-7.

PMID:
17554216
41.

Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.

Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528.

PMID:
17514017
42.

Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection.

Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y, Richman D, Little S.

Clin Infect Dis. 2007 Feb 1;44(3):456-8. Epub 2006 Dec 28.

PMID:
17205459
43.

Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.

Masquelier B, Capdepont S, Neau D, Peuchant O, Taupin JL, Coakley E, Lie Y, Carpentier W, Dabis F, Fleury HJ; ANRS CO3 Aquitaine Cohort.

AIDS. 2007 Jan 2;21(1):103-6.

PMID:
17148975
44.

Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.

Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

J Infect Dis. 2006 Dec 1;194(11):1505-9. Epub 2006 Oct 20.

PMID:
17083034
45.

Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naive Malawian women.

Eshleman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, Petropoulos CJ, Kumwenda N, Parkin N, Taha TE.

J Infect Dis. 2006 Jun 1;193(11):1512-5. Epub 2006 Apr 20.

PMID:
16652278
46.

Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.

Sévigny G, Stranix B, Tian B, Dubois A, Sauvé G, Petropoulos C, Lie Y, Hellmann N, Conway B, Yelle J.

Antiviral Res. 2006 Jun;70(2):17-20. Epub 2006 Jan 20.

PMID:
16473417
47.
48.

Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.

Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, Hellmann NS, Arens MQ.

J Clin Virol. 2004 Nov;31(3):198-203.

PMID:
15465412
49.

Identification of genes that regulate a left-right asymmetric neuronal migration in Caenorhabditis elegans.

Ch'ng Q, Williams L, Lie YS, Sym M, Whangbo J, Kenyon C.

Genetics. 2003 Aug;164(4):1355-67.

50.

Gender differences in education related health inequalities in Chinese northern rural areas: 1993 and 2001.

Wu J, Lie YL, Rao KQ, Qian JC, Ye RW, Sun Q, Li CY, Li Z.

J Epidemiol Community Health. 2003 Jul;57(7):506-7. No abstract available.

Supplemental Content

Support Center